Quoi de neuf en dermatologie pédiatrique

摘要: The association of a birth defect and segmental hemangioma is well established, consensus concerning evaluation monitoring infants with PHACE or LUMBAR syndromes has been published. efficacy propranolol in infantile proven; however there were still unresolved issues the safety children; after 8 years use on thousands children data collection did not show any unexpected side effects. Topical treatment hemangiomas beta-blockers, such as timolol, very popular, but recent publications revealed significant systemic absorption that could be responsible for severe effects, bradycardia, low birthweight infants. As consequence, this therapeutic option should considered caution. In last 2 mTOR inhibitors have tested low-flow vascular malformations varying success, progress remains to done abnormalities. Today, genetics led advances understanding pathophysiology future targeted therapies probably feasible. Skin barrier deficiency development allergic phenomena atopic patients, since it shown sensibilisation, even food, induced by skin contact. Unfortunately, topical crisaborole, phosphodiesterase 4 inhibitor, does look like revolution dermatitis, its seems equivalent emollient application. field infectious diseases, changes viral outbreaks are most reported. Furthermore epidemic Zika virus, enteroviruses expanded dermatological manifestations also meningoencephalitis. Paraviral character various eruptions, gloves socks syndrome eruptive pseudoangiomatosis challenged.